Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Epix Seeking New Partner For Blood Clot Imaging Agent EP-2104R

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Phase IIb trials will not begin without a partner after Schering AG relinquishes option.

You may also be interested in...



Epix President Andrew Uprichard: An Interview With "The Pink Sheet" DAILY

A day after Epix announces plans to further appeal two FDA "approvable" letters for Vasovist, Uprichard discusses why he's taking his case to CDER Director Steve Galson.

Epix President Andrew Uprichard: An Interview With "The Pink Sheet" DAILY

A day after Epix announces plans to further appeal two FDA "approvable" letters for Vasovist, Uprichard discusses why he's taking his case to CDER Director Steve Galson.

Epix’ Antidepressant Needs Big Pharma Partner For Launch

Opportunity seen in companies with antidepressants that are off-patent or don’t have follow-ons.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS064498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By